Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours

BACKGROUND: This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours. METHODS: Eligible patients with ECOG PS 0–1 were treated with eribulin-LF either on day 1 every 21 days...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Cancer
Glavni autori: Evans, T. R. Jeffry, Dean, Emma, Molife, L. Rhoda, Lopez, Juanita, Ranson, Malcolm, El-Khouly, Fatima, Zubairi, Ishtiaq, Savulsky, Claudio, Reyderman, Larisa, Jia, Yan, Sweeting, Lorna, Greystoke, Alastair, Barriuso, Jorge, Kristeleit, Rebecca
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2019
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6461749/
https://ncbi.nlm.nih.gov/pubmed/30679780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0377-x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items